Round Up

Five things for pharma marketers to know: Tuesday, March 21, 2017

Five things for pharma marketers to know: Tuesday, March 21, 2017

By

Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised

Five things for pharma marketers to know: Thursday, March 9, 2017

Five things for pharma marketers to know: Thursday, March 9, 2017

Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled

Five things for pharma marketers to know: Tuesday, March 7, 2017

Five things for pharma marketers to know: Tuesday, March 7, 2017

By

GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies

Five things for pharma marketers to know: Monday, February 27, 2017

Five things for pharma marketers to know: Monday, February 27, 2017

By

Pfizer receives subpoena over patient assistance programs; drugmakers raise prices less this January than last; lawmakers have new plan to repeal ACA

Five things for pharma marketers to know: Thursday, February 23, 2017

Five things for pharma marketers to know: Thursday, February 23, 2017

By

Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review

Five things for pharma marketers to know: Wednesday, February 22, 2017

Five things for pharma marketers to know: Wednesday, February 22, 2017

By

Audit says MD Anderson Cancer Center mismanaged Watson partnership; Icahn takes stake in BMS; Sarepta sells priority review voucher to Gilead

Five things for pharma marketers to know: Wednesday, February 8, 2017

Five things for pharma marketers to know: Wednesday, February 8, 2017

By

Sanofi is not in a hurry to make a deal; Spicer says Trump supports Medicare drug price negotiations; HCV market is shrinking, Gilead execs say

Five things for pharma marketers to know: Wednesday, February 1, 2017

Five things for pharma marketers to know: Wednesday, February 1, 2017

By

Trump wants to speed up drug approvals; Sanofi allergy drug gets OTC approval; Lilly ends final solanezumab trial

Five things for pharma marketers to know: Friday January 27, 2017

Five things for pharma marketers to know: Friday January 27, 2017

By

BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup

Five things for pharma marketers to know: Monday, January 23, 2017

Five things for pharma marketers to know: Monday, January 23, 2017

By

BMS and Ono settle Keytruda patent suit; PhRMA plans to release new campaign; Trump moves forward with plans to scale back the ACA

Five things for pharma marketers to know: Thursday, January 19, 2017

Five things for pharma marketers to know: Thursday, January 19, 2017

By

The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma

 Five things for pharma marketers to know: Friday, January 13, 2017

Five things for pharma marketers to know: Friday, January 13, 2017

By

CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal

Five things for pharma marketers to know: Wednesday, January 11, 2017

Five things for pharma marketers to know: Wednesday, January 11, 2017

By

The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts

Five things for pharma marketers to know: Thursday, January 5, 2017

Five things for pharma marketers to know: Thursday, January 5, 2017

By

Orexigen launches new campaign for weight-loss drug Contrave; Arena sells Belviq to Eisai; Alexion reportedly pushed for 'pull-in' sales

Five things for pharma marketers to know: Thursday, December 22, 2016

Five things for pharma marketers to know: Thursday, December 22, 2016

By

Senate report said certain drugmakers act like hedge funds; ViiV to develop HIV prevention drug; lawmakers to replace ACA with "universal access"

Five things for pharma marketers to know: Tuesday, December 20, 2016

Five things for pharma marketers to know: Tuesday, December 20, 2016

By

Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm

Five things for pharma marketers to know: Tuesday, November 15, 2016

Five things for pharma marketers to know: Tuesday, November 15, 2016

By

The CMS spent more on Harvoni than any other drug; Novartis considers selling Alcon; the EMA recommends approval of Lantus biosimilar

Five things for pharma marketers to know: Monday, October 31, 2016

Five things for pharma marketers to know: Monday, October 31, 2016

By

Shares decline on news drugmakers will limit price hikes; AstraZeneca said it will leave UK if country doesn't pay for new drugs; Astellas acquires Ganymed

Five things for pharma marketers to know: Wednesday, October 26, 2016

Five things for pharma marketers to know: Wednesday, October 26, 2016

By

Novartis CEO said pricing environment to worsen; Purdue Pharma offered PBM rebates to get around oxycodone prior authorization; Express Scripts subpoenaed

Five things for pharma marketers to know: Thursday, October 20, 2016

Five things for pharma marketers to know: Thursday, October 20, 2016

By

Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug

Five things for pharma marketers to know: Thursday, October 13, 2016

Five things for pharma marketers to know: Thursday, October 13, 2016

By

Aetna inks value-based deal with Merck in diabetes; new research claims co-pay cards increased drug spend; Xarelto data not affected by device

Five things for pharma marketers to know: Wednesday, October 12, 2016

Five things for pharma marketers to know: Wednesday, October 12, 2016

By

Valeant is under fire for another price hike; Novartis and Queen Latifah raise awareness about heart failure; critics take aim at co-pay programs

Five things for pharma marketers to know: Thursday, October 6, 2016

Five things for pharma marketers to know: Thursday, October 6, 2016

By

Xarelto may cause patients to have more serious bleeding episodes; devicemaker acquires Pfizer's infusion business; Theranos shutters laboratory operations

Five things for pharma marketers to know: Tuesday, September 27, 2016

Five things for pharma marketers to know: Tuesday, September 27, 2016

By

Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest

Five things for pharma marketers to know: Friday, September 2, 2016

Five things for pharma marketers to know: Friday, September 2, 2016

By

Hillary Clinton releases drug-pricing plan; patent for Teva's Copaxone is invalidated; Roche's immunotherapy extends life

Five things for pharma marketers to know: Wednesday, August 17, 2016

Five things for pharma marketers to know: Wednesday, August 17, 2016

By

AHIP study says half of orphan-drug usage is for non-orphan indications; Studies of GSK weight-loss pill underestimated side effects; ViiV starts HIV trial

Five things for pharma marketers to know: Monday, August 15, 2016

Five things for pharma marketers to know: Monday, August 15, 2016

By

Express Scripts does not disclose names of formulary board members; Endo withdrew abuse-deterrent formulation for opioid; BI to collect real-world data on Praxbind

OPINION

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Newsletters